메뉴 건너뛰기




Volumn 5, Issue DEC, 2015, Pages

Aurora kinase inhibitors: Current status and outlook

Author keywords

Aurora kinase; Hematologic diseases; Kinase inhibitors; Neuroblastoma; Small molecules

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ALISERTIB; AMG 900; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; BARASERTIB; DANUSERTIB; PF 3814735; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

EID: 84954551780     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00278     Document Type: Review
Times cited : (222)

References (91)
  • 1
    • 0032100685 scopus 로고    scopus 로고
    • A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
    • BischoffJR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 17:3052-65. doi: 10.1093/emboj/17.11.3052.
    • (1998) EMBO J , vol.17 , pp. 3052-3065
    • Bischoff, J.R.1    Anderson, L.2    Zhu, Y.3    Mossie, K.4    Ng, L.5    Souza, B.6
  • 2
    • 0242551545 scopus 로고    scopus 로고
    • The cellular geography of aurora kinases
    • Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol (2003) 4:842-54. doi:10.1038/nrm1245.
    • (2003) Nat Rev Mol Cell Biol , vol.4 , pp. 842-854
    • Carmena, M.1    Earnshaw, W.C.2
  • 3
    • 0032716628 scopus 로고    scopus 로고
    • Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases
    • Giet R, Prigent C. Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J Cell Sci (1999) 112:3591-601.
    • (1999) J Cell Sci , vol.112 , pp. 3591-3601
    • Giet, R.1    Prigent, C.2
  • 5
    • 39049166077 scopus 로고    scopus 로고
    • Aurora kinase inhibitors: identification and preclinical validation of their biomarkers
    • Carpinelli P, Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin Ther Targets (2008) 12:69-80. doi:10.1517/14728222.12.1.69.
    • (2008) Expert Opin Ther Targets , vol.12 , pp. 69-80
    • Carpinelli, P.1    Moll, J.2
  • 7
    • 33745275629 scopus 로고    scopus 로고
    • The chromosomal passenger complex: guiding aurora-B through mitosis
    • Vader G, Medema RH, Lens SM. The chromosomal passenger complex: guiding aurora-B through mitosis. J Cell Biol (2006) 173:833-7. doi:10.1083/jcb.200604032.
    • (2006) J Cell Biol , vol.173 , pp. 833-837
    • Vader, G.1    Medema, R.H.2    Lens, S.M.3
  • 8
    • 3242657509 scopus 로고    scopus 로고
    • The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly
    • Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A, Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell (2004) 118:187-202. doi:10.1016/j.cell.2004.06.026.
    • (2004) Cell , vol.118 , pp. 187-202
    • Sampath, S.C.1    Ohi, R.2    Leismann, O.3    Salic, A.4    Pozniakovski, A.5    Funabiki, H.6
  • 9
    • 0032472915 scopus 로고    scopus 로고
    • AIM-1: a mammalian midbody-associated protein required for cytokinesis
    • Terada Y, Tatsuka M, Suzuki F, Yasuda Y, Fujita S, Otsu M. AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J (1998) 17:667-76. doi:10.1093/emboj/17.3.667.
    • (1998) EMBO J , vol.17 , pp. 667-676
    • Terada, Y.1    Tatsuka, M.2    Suzuki, F.3    Yasuda, Y.4    Fujita, S.5    Otsu, M.6
  • 10
    • 84870192369 scopus 로고    scopus 로고
    • The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis
    • Carmena M, Wheelock M, Funabiki H, Earnshaw WC. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol (2012) 13:789-803. doi:10.1038/nrm3474.
    • (2012) Nat Rev Mol Cell Biol , vol.13 , pp. 789-803
    • Carmena, M.1    Wheelock, M.2    Funabiki, H.3    Earnshaw, W.C.4
  • 11
    • 80052033722 scopus 로고    scopus 로고
    • A complex of Kif18b and MCAK promotes microtubule depolymerization and is negatively regulated by aurora kinases
    • Tanenbaum ME, Macurek L, van der Vaart B, Galli M, Akhmanova A, Medema RH. A complex of Kif18b and MCAK promotes microtubule depolymerization and is negatively regulated by aurora kinases. Curr Biol (2011) 21:1356-65. doi:10.1016/j.cub.2011.07.017.
    • (2011) Curr Biol , vol.21 , pp. 1356-1365
    • Tanenbaum, M.E.1    Macurek, L.2    van der Vaart, B.3    Galli, M.4    Akhmanova, A.5    Medema, R.H.6
  • 12
    • 33744949918 scopus 로고    scopus 로고
    • Expression of aurora kinases in human thyroid carcinoma cell lines and tissues
    • Ulisse S, Delcros JG, Baldini E, Toller M, Curcio F, Giacomelli L, et al. Expression of aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer (2006) 119:275-82. doi:10.1002/ijc.21842.
    • (2006) Int J Cancer , vol.119 , pp. 275-282
    • Ulisse, S.1    Delcros, J.G.2    Baldini, E.3    Toller, M.4    Curcio, F.5    Giacomelli, L.6
  • 13
    • 0032212717 scopus 로고    scopus 로고
    • Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter
    • Bernard M, Sanseau P, Henry C, Couturier A, Prigent C. Cloning of STK13, a third human protein kinase related to Drosophila aurora and budding yeast Ipl1 that maps on chromosome 19q13.3-ter. Genomics (1998) 53:406-9. doi:10.1006/geno.1998.5522.
    • (1998) Genomics , vol.53 , pp. 406-409
    • Bernard, M.1    Sanseau, P.2    Henry, C.3    Couturier, A.4    Prigent, C.5
  • 14
    • 0033548619 scopus 로고    scopus 로고
    • Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3
    • Kimura M, Matsuda Y, Yoshioka T, Okano Y. Cell cycle-dependent expression and centrosome localization of a third human aurora/Ipl1-related protein kinase, AIK3. J Biol Chem (1999) 274:7334-40. doi:10.1074/jbc.274.11.7334.
    • (1999) J Biol Chem , vol.274 , pp. 7334-7340
    • Kimura, M.1    Matsuda, Y.2    Yoshioka, T.3    Okano, Y.4
  • 15
    • 77954640078 scopus 로고    scopus 로고
    • Aurora-C kinase deficiency causes cytokinesis failure in meiosis-I and production of large polyploid oocytes in mouse
    • Yang KT, Li SK, Chang CC, Tang CJ, Lin YN, Lee SC, et al. Aurora-C kinase deficiency causes cytokinesis failure in meiosis-I and production of large polyploid oocytes in mouse. Mol Biol Cell (2010) 21:2371-83. doi:10.1091/mbc. E10-02-0170.
    • (2010) Mol Biol Cell , vol.21 , pp. 2371-2383
    • Yang, K.T.1    Li, S.K.2    Chang, C.C.3    Tang, C.J.4    Lin, Y.N.5    Lee, S.C.6
  • 16
    • 80055040429 scopus 로고    scopus 로고
    • Overexpression of active aurora-C kinase results in cell transformation and tumour formation
    • Khan J, Ezan F, Crémet JY, Fautrel A, Gilot D, Lambert M, et al. Overexpression of active aurora-C kinase results in cell transformation and tumour formation. PLoS One (2011) 6:e26512. doi:10.1371/journal.pone.0026512.
    • (2011) PLoS One , vol.6
    • Khan, J.1    Ezan, F.2    Crémet, J.Y.3    Fautrel, A.4    Gilot, D.5    Lambert, M.6
  • 17
    • 0031714080 scopus 로고    scopus 로고
    • Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
    • Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet (1998) 20:189-93. doi:10.1038/2496.
    • (1998) Nat Genet , vol.20 , pp. 189-193
    • Zhou, H.1    Kuang, J.2    Zhong, L.3    Kuo, W.L.4    Gray, J.W.5    Sahin, A.6
  • 18
    • 0037386929 scopus 로고    scopus 로고
    • Activation and overexpression of centrosome kinase BTAK/aurora-A in human ovarian cancer
    • Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, et al. Activation and overexpression of centrosome kinase BTAK/aurora-A in human ovarian cancer. Clin Cancer Res (2003) 9:1420-6.
    • (2003) Clin Cancer Res , vol.9 , pp. 1420-1426
    • Gritsko, T.M.1    Coppola, D.2    Paciga, J.E.3    Yang, L.4    Sun, M.5    Shelley, S.A.6
  • 19
    • 0033135640 scopus 로고    scopus 로고
    • Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast
    • Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res (1999) 59:2041-4.
    • (1999) Cancer Res , vol.59 , pp. 2041-2044
    • Tanaka, T.1    Kimura, M.2    Matsunaga, K.3    Fukada, D.4    Mori, H.5    Okano, Y.6
  • 20
    • 2142746397 scopus 로고    scopus 로고
    • The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas
    • Reichardt W, Jung V, Brunner C, Klein A, Wemmert S, Romeike BF, et al. The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas. Oncol Rep (2003) 10:1275-9.
    • (2003) Oncol Rep , vol.10 , pp. 1275-1279
    • Reichardt, W.1    Jung, V.2    Brunner, C.3    Klein, A.4    Wemmert, S.5    Romeike, B.F.6
  • 21
    • 1842589396 scopus 로고    scopus 로고
    • High expression of aurora-B/aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas
    • Araki K, Nozaki K, Ueba T, Tatsuka M, Hashimoto N. High expression of aurora-B/aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J Neurooncol (2004) 67:53-64. doi:10.1023/B:NEON.0000021784.33421.05.
    • (2004) J Neurooncol , vol.67 , pp. 53-64
    • Araki, K.1    Nozaki, K.2    Ueba, T.3    Tatsuka, M.4    Hashimoto, N.5
  • 23
    • 20044390030 scopus 로고    scopus 로고
    • Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation
    • Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab (2005) 90:928-35. doi:10.1210/jc.2004-1518.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 928-935
    • Sorrentino, R.1    Libertini, S.2    Pallante, P.L.3    Troncone, G.4    Palombini, L.5    Bavetsias, V.6
  • 24
    • 18044391525 scopus 로고    scopus 로고
    • Aurora kinases, aneuploidy and cancer, a coincidence or a real link?
    • Giet R, Petretti C, Prigent C. Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol (2005) 15:241-50. doi:10.1016/j.tcb.2005.03.004.
    • (2005) Trends Cell Biol , vol.15 , pp. 241-250
    • Giet, R.1    Petretti, C.2    Prigent, C.3
  • 25
    • 67651146527 scopus 로고    scopus 로고
    • Determinants for the efficiency of anticancer drugs targeting either aurora-A or aurora-B kinases in human colon carcinoma cells
    • Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either aurora-A or aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther (2009) 8:2046-56. doi:10.1158/1535-7163.MCT-09-0323.
    • (2009) Mol Cancer Ther , vol.8 , pp. 2046-2056
    • Kaestner, P.1    Stolz, A.2    Bastians, H.3
  • 26
    • 57849107571 scopus 로고    scopus 로고
    • Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma
    • Otto T, Horn S, Brockmann M, Eilers U, Schüttrumpf L, Popov N, et al. Stabilization of N-Myc is a critical function of aurora A in human neuroblastoma. Cancer Cell (2009) 15:67-78. doi:10.1016/j.ccr.2008.12.005.
    • (2009) Cancer Cell , vol.15 , pp. 67-78
    • Otto, T.1    Horn, S.2    Brockmann, M.3    Eilers, U.4    Schüttrumpf, L.5    Popov, N.6
  • 28
    • 34247603906 scopus 로고    scopus 로고
    • Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase
    • Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann J-JM, et al. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem (2007) 50:2213-24. doi:10.1021/jm061335f.
    • (2007) J Med Chem , vol.50 , pp. 2213-2224
    • Mortlock, A.A.1    Foote, K.M.2    Heron, N.M.3    Jung, F.H.4    Pasquet, G.5    Lohmann, J.-J.M.6
  • 29
    • 84866434859 scopus 로고    scopus 로고
    • Phase I study of the aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
    • Dennis M, Davies M, Oliver S, D'Souza R, Pike L, Stockman P. Phase I study of the aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia. Cancer Chemother Pharmacol (2012) 70:461-9. doi:10.1007/s00280-012-1939-2.
    • (2012) Cancer Chemother Pharmacol , vol.70 , pp. 461-469
    • Dennis, M.1    Davies, M.2    Oliver, S.3    D'Souza, R.4    Pike, L.5    Stockman, P.6
  • 30
    • 79251556865 scopus 로고    scopus 로고
    • Clinical evaluation of AZD1152, an i.v. inhibitor of aurora B kinase, in patients with solid malignant tumors
    • Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of aurora B kinase, in patients with solid malignant tumors. Ann Oncol (2011) 22:431-7. doi:10.1093/annonc/mdq344.
    • (2011) Ann Oncol , vol.22 , pp. 431-437
    • Boss, D.S.1    Witteveen, P.O.2    van der Sar, J.3    Lolkema, M.P.4    Voest, E.E.5    Stockman, P.K.6
  • 31
    • 84879554441 scopus 로고    scopus 로고
    • Phase I study of barasertib (AZD1152), a selective inhibitor of aurora B kinase, in patients with advanced solid tumors
    • Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of aurora B kinase, in patients with advanced solid tumors. Invest New Drugs (2013) 31:370-80. doi:10.1007/s10637-012-9825-7.
    • (2013) Invest New Drugs , vol.31 , pp. 370-380
    • Schwartz, G.K.1    Carvajal, R.D.2    Midgley, R.3    Rodig, S.J.4    Stockman, P.K.5    Ataman, O.6
  • 32
    • 82955217793 scopus 로고    scopus 로고
    • Phase1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced myeloid leukemia
    • Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn J-Y, Ifrah N, et al. Phase1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced myeloid leukemia. Blood (2011) 118:6030-6. doi:10.1182/blood-2011-07-366930.
    • (2011) Blood , vol.118 , pp. 6030-6036
    • Lowenberg, B.1    Muus, P.2    Ossenkoppele, G.3    Rousselot, P.4    Cahn, J.-Y.5    Ifrah, N.6
  • 33
    • 80052100694 scopus 로고    scopus 로고
    • A phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia
    • Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, et al. A phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res (2011) 35:1384-9. doi:10.1016/j.leukres.2011.04.008.
    • (2011) Leuk Res , vol.35 , pp. 1384-1389
    • Tsuboi, K.1    Yokozawa, T.2    Sakura, T.3    Watanabe, T.4    Fujisawa, S.5    Yamauchi, T.6
  • 34
    • 84884155615 scopus 로고    scopus 로고
    • Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
    • Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, et al. Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk (2013) 13:559-67. doi:10.1016/j.clml.2013.03.019.
    • (2013) Clin Lymphoma Myeloma Leuk , vol.13 , pp. 559-567
    • Kantarjian, H.M.1    Sekeres, M.A.2    Ribrag, V.3    Rousselot, P.4    Garcia-Manero, G.5    Jabbour, E.J.6
  • 35
    • 84879644165 scopus 로고    scopus 로고
    • Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
    • Kantarjian HM, Martinelli G, Jabbour EJ, Quintas-Cardama A, Ando K, Bay J-O, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer (2013) 119(14):2611-9. doi:10.1002/cncr.28113.
    • (2013) Cancer , vol.119 , Issue.14 , pp. 2611-2619
    • Kantarjian, H.M.1    Martinelli, G.2    Jabbour, E.J.3    Quintas-Cardama, A.4    Ando, K.5    Bay, J.-O.6
  • 36
    • 84055217855 scopus 로고    scopus 로고
    • Characterisation of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays
    • Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, et al. Characterisation of alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res (2011) 17:7614-24. doi:10.1158/1078-0432.CCR-11-1536.
    • (2011) Clin Cancer Res , vol.17 , pp. 7614-7624
    • Manfredi, M.G.1    Ecsedy, J.A.2    Chakravarty, A.3    Silverman, L.4    Zhang, M.5    Hoar, K.M.6
  • 37
    • 84935924815 scopus 로고    scopus 로고
    • MLN8054 and alisertib (MLN8237): discovery of selective oral aurora A inhibitors
    • Sells TB, Chau R, Ecsedy JA, Gershman RE, Hoar K, Huck J, et al. MLN8054 and alisertib (MLN8237): discovery of selective oral aurora A inhibitors. ACS Med Chem Lett (2015) 6:630-4. doi:10.1021/ml500409n.
    • (2015) ACS Med Chem Lett , vol.6 , pp. 630-634
    • Sells, T.B.1    Chau, R.2    Ecsedy, J.A.3    Gershman, R.E.4    Hoar, K.5    Huck, J.6
  • 38
    • 82455192242 scopus 로고    scopus 로고
    • Efficacy and pharmacokinetic/pharmacodynamics evaluation of the aurora kinase inhibitor MLN8237 against preclinical models of pediatric cancer
    • Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, et al. Efficacy and pharmacokinetic/pharmacodynamics evaluation of the aurora kinase inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 68:1291-304. doi:10.1007/s00280-011-1618-8.
    • (2011) Cancer Chemother Pharmacol , vol.68 , pp. 1291-1304
    • Carol, H.1    Boehm, I.2    Reynolds, C.P.3    Kang, M.H.4    Maris, J.M.5    Morton, C.L.6
  • 39
    • 84867071565 scopus 로고    scopus 로고
    • Targeting aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism
    • Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, Padmanabhan S, et al. Targeting aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer (2012) 131:2693-703. doi:10.1002/ijc.27579.
    • (2012) Int J Cancer , vol.131 , pp. 2693-2703
    • Kelly, K.R.1    Nawrocki, S.T.2    Espitia, C.M.3    Zhang, M.4    Yang, J.J.5    Padmanabhan, S.6
  • 40
    • 79957528550 scopus 로고    scopus 로고
    • The novel aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib
    • Kelly KR, Ecsedy J, Medina E, Mahalingam D, Padmanabhan S, Nawrocki ST, et al. The novel aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib. J Cell Mol Med (2011) 15:2057-70. doi:10.1111/j.1582-4934.2010.01218.x.
    • (2011) J Cell Mol Med , vol.15 , pp. 2057-2070
    • Kelly, K.R.1    Ecsedy, J.2    Medina, E.3    Mahalingam, D.4    Padmanabhan, S.5    Nawrocki, S.T.6
  • 41
    • 84865741266 scopus 로고    scopus 로고
    • Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations
    • Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, et al. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res (2012) 18:4775-84. doi:10.1158/1078-0432.CCR-12-0589.
    • (2012) Clin Cancer Res , vol.18 , pp. 4775-4784
    • Dees, E.C.1    Cohen, R.B.2    von Mehren, M.3    Stinchcombe, T.E.4    Liu, H.5    Venkatakrishnan, K.6
  • 42
    • 84865700741 scopus 로고    scopus 로고
    • Phase I pharmacokinetic/pharmacodynamics study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors
    • Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, et al. Phase I pharmacokinetic/pharmacodynamics study of MLN8237, an investigational, oral, selective aurora A kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res (2012) 18:4764-74. doi:10.1158/1078-0432.CCR-12-0571.
    • (2012) Clin Cancer Res , vol.18 , pp. 4764-4774
    • Cervantes, A.1    Elez, E.2    Roda, D.3    Ecsedy, J.4    Macarulla, T.5    Venkatakrishnan, K.6
  • 43
    • 84865681647 scopus 로고    scopus 로고
    • Phase II study of MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    • Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, et al. Phase II study of MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol (2012) 127:63-9. doi:10.1016/j.ygyno.2012.06.040.
    • (2012) Gynecol Oncol , vol.127 , pp. 63-69
    • Matulonis, U.A.1    Sharma, S.2    Ghamande, S.3    Gordon, M.S.4    Del Prete, S.A.5    Ray-Coquard, I.6
  • 44
    • 84868542839 scopus 로고    scopus 로고
    • Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of aurora kinase A: a children's oncology group phase I consortium study
    • Mosse YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, et al. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of aurora kinase A: a children's oncology group phase I consortium study. Clin Cancer Res (2012) 18:6058-64. doi:10.1158/1078-0432.CCR-11-3251.
    • (2012) Clin Cancer Res , vol.18 , pp. 6058-6064
    • Mosse, Y.P.1    Lipsitz, E.2    Fox, E.3    Teachey, D.T.4    Maris, J.M.5    Weigel, B.6
  • 45
    • 84904579971 scopus 로고    scopus 로고
    • Phase I study of MLN8237-investigational aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, et al. Phase I study of MLN8237-investigational aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs (2014) 32:489-99. doi:10.1007/s10637-013-0050-9.
    • (2014) Invest New Drugs , vol.32 , pp. 489-499
    • Kelly, K.R.1    Shea, T.C.2    Goy, A.3    Berdeja, J.G.4    Reeder, C.B.5    McDonagh, K.T.6
  • 46
    • 84892916318 scopus 로고    scopus 로고
    • Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell Non-Hodgkin lymphomas
    • Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al. Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell Non-Hodgkin lymphomas. J Clin Oncol (2014) 32:44-50. doi:10.1200/JCO.2012.46.8793.
    • (2014) J Clin Oncol , vol.32 , pp. 44-50
    • Friedberg, J.W.1    Mahadevan, D.2    Cebula, E.3    Persky, D.4    Lossos, I.5    Agarwal, A.B.6
  • 47
    • 84907486048 scopus 로고    scopus 로고
    • An exploratory phase 2 study of investigational aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
    • Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, et al. An exploratory phase 2 study of investigational aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res Rep (2014) 3:58-61. doi:10.1016/j.lrr.2014.06.003.
    • (2014) Leuk Res Rep , vol.3 , pp. 58-61
    • Goldberg, S.L.1    Fenaux, P.2    Craig, M.D.3    Gyan, E.4    Lister, J.5    Kassis, J.6
  • 48
    • 33845367377 scopus 로고    scopus 로고
    • 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile
    • Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem (2006) 49:7247-51. doi:10.1021/jm060897w.
    • (2006) J Med Chem , vol.49 , pp. 7247-7251
    • Fancelli, D.1    Moll, J.2    Varasi, M.3    Bravo, R.4    Artico, R.5    Berta, D.6
  • 49
    • 37549071104 scopus 로고    scopus 로고
    • PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer
    • Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, et al. PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther (2007) 6:3158-68. doi:10.1158/1535-7163.MCT-07-0444.
    • (2007) Mol Cancer Ther , vol.6 , pp. 3158-3168
    • Carpinelli, P.1    Ceruti, R.2    Giorgini, M.L.3    Cappella, P.4    Gianellini, L.5    Croci, V.6
  • 50
    • 34548548332 scopus 로고    scopus 로고
    • Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358
    • Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res (2007) 67:7987-90. doi:10.1158/0008-5472.CAN-07-1825.
    • (2007) Cancer Res , vol.67 , pp. 7987-7990
    • Modugno, M.1    Casale, E.2    Soncini, C.3    Rosettani, P.4    Colombo, R.5    Lupi, R.6
  • 51
    • 73549111210 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors
    • Steeghs N, Eskens FALM, Gelderblom H, Verweij J, Nortier JWR, Ouwerkerk J, et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol (2009) 27:5094-101. doi:10.1200/JCO.2008.21.6655.
    • (2009) J Clin Oncol , vol.27 , pp. 5094-5101
    • Steeghs, N.1    Eskens, F.A.L.M.2    Gelderblom, H.3    Verweij, J.4    Nortier, J.W.R.5    Ouwerkerk, J.6
  • 52
    • 84939603153 scopus 로고    scopus 로고
    • Efficacy and safety of biweekly i.v. administrations of the aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumor, multi-institutional phase II study
    • Schoffski P, Besse B, Gauler T, de Jonge MJA, Scambia G, Santoro A, et al. Efficacy and safety of biweekly i.v. administrations of the aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumor, multi-institutional phase II study. Ann Oncol (2015) 26:598-607. doi:10.1093/annonc/mdu566.
    • (2015) Ann Oncol , vol.26 , pp. 598-607
    • Schoffski, P.1    Besse, B.2    Gauler, T.3    de Jonge, M.J.A.4    Scambia, G.5    Santoro, A.6
  • 53
    • 84871613362 scopus 로고    scopus 로고
    • Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
    • Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int (2013) 111:44-52. doi:10.1111/j.1464-410X.2012.11404.x.
    • (2013) BJU Int , vol.111 , pp. 44-52
    • Meulenbeld, H.J.1    Bleuse, J.P.2    Vinci, E.M.3    Raymond, E.4    Vitali, G.5    Santoro, A.6
  • 54
    • 70350707750 scopus 로고    scopus 로고
    • A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors
    • Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 15:6694-701. doi:10.1158/1078-0432.CCR-09-1445.
    • (2009) Clin Cancer Res , vol.15 , pp. 6694-6701
    • Cohen, R.B.1    Jones, S.F.2    Aggarwal, C.3    von Mehren, M.4    Cheng, J.5    Spigel, D.R.6
  • 56
    • 84936127226 scopus 로고    scopus 로고
    • A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
    • Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N, Jabbour E, et al. A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy. Haematologica (2015) 100:898-904. doi:10.3324/haematol.2014.115279.
    • (2015) Haematologica , vol.100 , pp. 898-904
    • Borthakur, G.1    Dombret, H.2    Schafhausen, P.3    Brummendorf, T.H.4    Boissel, N.5    Jabbour, E.6
  • 57
    • 60549088370 scopus 로고    scopus 로고
    • Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity
    • Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem (2009) 52:379-88. doi:10.1021/jm800984v.
    • (2009) J Med Chem , vol.52 , pp. 379-388
    • Howard, S.1    Berdini, V.2    Boulstridge, J.A.3    Carr, M.G.4    Cross, D.M.5    Curry, J.6
  • 58
    • 77957201111 scopus 로고    scopus 로고
    • Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
    • Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, et al. Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. Blood (2010) 116:2089-95. doi:10.1182/blood-2009-03-211466.
    • (2010) Blood , vol.116 , pp. 2089-2095
    • Tanaka, R.1    Squires, M.S.2    Kimura, S.3    Yokota, A.4    Nagao, R.5    Yamauchi, T.6
  • 59
    • 67649345473 scopus 로고    scopus 로고
    • Aurora B kinase inhibition in mitosis, strategies for optimising the use of aurora kinase inhibitors such as AT9283
    • Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N, et al. Aurora B kinase inhibition in mitosis, strategies for optimising the use of aurora kinase inhibitors such as AT9283. Cell Cycle (2009) 8:1921-9. doi:10.4161/cc.8.12.8741.
    • (2009) Cell Cycle , vol.8 , pp. 1921-1929
    • Curry, J.1    Angove, H.2    Fazal, L.3    Lyons, J.4    Reule, M.5    Thompson, N.6
  • 60
    • 84859890125 scopus 로고    scopus 로고
    • AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas
    • Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer (2012) 130:2997-3005. doi:10.1002/ijc.26324.
    • (2012) Int J Cancer , vol.130 , pp. 2997-3005
    • Qi, W.1    Liu, X.2    Cooke, L.S.3    Persky, D.O.4    Miller, T.P.5    Squires, M.6
  • 61
    • 84860485132 scopus 로고    scopus 로고
    • A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies
    • Arkenau H-T, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol (2012) 23:1307-13. doi:10.1093/annonc/mdr451.
    • (2012) Ann Oncol , vol.23 , pp. 1307-1313
    • Arkenau, H.-T.1    Plummer, R.2    Molife, L.R.3    Olmos, D.4    Yap, T.A.5    Squires, M.6
  • 62
    • 84888620601 scopus 로고    scopus 로고
    • NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
    • Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, et al. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. Invest New Drugs (2013) 31:1522-9. doi:10.1007/s10637-013-0018-9.
    • (2013) Invest New Drugs , vol.31 , pp. 1522-1529
    • Dent, S.F.1    Gelmon, K.A.2    Chi, K.N.3    Jonker, D.J.4    Wainman, N.5    Capier, C.A.6
  • 63
    • 84920983167 scopus 로고    scopus 로고
    • A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a cancer research UK study
    • Moreno L, Marshall LV, Pearson ADJ, Morland B, Elliott M, Campbell-Hewson Q, et al. A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a cancer research UK study. Clin Cancer Res (2015) 21:267-73. doi:10.1158/1078-0432.CCR-14-1592.
    • (2015) Clin Cancer Res , vol.21 , pp. 267-273
    • Moreno, L.1    Marshall, L.V.2    Pearson, A.D.J.3    Morland, B.4    Elliott, M.5    Campbell-Hewson, Q.6
  • 64
    • 84900000570 scopus 로고    scopus 로고
    • A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis
    • Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, et al. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk (2014) 14:223-30. doi:10.1016/j.clml.2013.11.001.
    • (2014) Clin Lymphoma Myeloma Leuk , vol.14 , pp. 223-230
    • Foran, J.1    Ravandi, F.2    Wierda, W.3    Garcia-Manero, G.4    Verstovsek, S.5    Kadia, T.6
  • 65
    • 77950821678 scopus 로고    scopus 로고
    • PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy
    • Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, et al. PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther (2010) 9:883-94. doi:10.1158/1535-7163.MCT-09-0915.
    • (2010) Mol Cancer Ther , vol.9 , pp. 883-894
    • Jani, J.P.1    Arcari, J.2    Bernardo, V.3    Bhattacharya, S.K.4    Briere, D.5    Cohen, B.D.6
  • 66
    • 80053353928 scopus 로고    scopus 로고
    • Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumors
    • Schoffski P, Jones SF, Dumez H, Infante JR, Mieghem EV, Fowst C, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumors. Eur J Cancer (2011) 47:2256-64. doi:10.1016/j.ejca.2011.07.008.
    • (2011) Eur J Cancer , vol.47 , pp. 2256-2264
    • Schoffski, P.1    Jones, S.F.2    Dumez, H.3    Infante, J.R.4    Mieghem, E.V.5    Fowst, C.6
  • 67
    • 78649971294 scopus 로고    scopus 로고
    • Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines
    • Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res (2010) 70:9846-54. doi:10.1158/0008-5472.CAN-10-3001.
    • (2010) Cancer Res , vol.70 , pp. 9846-9854
    • Payton, M.1    Bush, T.L.2    Chung, G.3    Ziegler, B.4    Eden, P.5    McElroy, P.6
  • 68
    • 84937458803 scopus 로고    scopus 로고
    • Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridine-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cell lines
    • Geuns-Meyer S, Cee VJ, Deak HL, Du B, Hodous BL, Nguyen HN, et al. Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridine-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cell lines. J Med Chem (2015) 58:5189-207. doi:10.1021/acs.jmedchem.5b00183.
    • (2015) J Med Chem , vol.58 , pp. 5189-5207
    • Geuns-Meyer, S.1    Cee, V.J.2    Deak, H.L.3    Du, B.4    Hodous, B.L.5    Nguyen, H.N.6
  • 69
    • 84937468263 scopus 로고    scopus 로고
    • Aurora kinase inhibition: a new light in the sky?
    • Linardopoulos S, Blagg J. Aurora kinase inhibition: a new light in the sky? J Med Chem (2015) 58:5186-8. doi:10.1021/acs.jmedchem.5b00918.
    • (2015) J Med Chem , vol.58 , pp. 5186-5188
    • Linardopoulos, S.1    Blagg, J.2
  • 70
    • 84887420572 scopus 로고    scopus 로고
    • AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models
    • Bush TL, Payton M, Heller S, Chung G, Hanestad K, Rottman JB, et al. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Mol Cancer Ther (2013) 12:2356-66. doi:10.1158/1535-7163.MCT-12-1178.
    • (2013) Mol Cancer Ther , vol.12 , pp. 2356-2366
    • Bush, T.L.1    Payton, M.2    Heller, S.3    Chung, G.4    Hanestad, K.5    Rottman, J.B.6
  • 71
    • 77950949478 scopus 로고    scopus 로고
    • Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias
    • Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia (2010) 24:671-8. doi:10.1038/leu.2010.15.
    • (2010) Leukemia , vol.24 , pp. 671-678
    • Moore, A.S.1    Blagg, J.2    Linardopoulos, S.3    Pearson, A.D.4
  • 72
    • 34548822673 scopus 로고    scopus 로고
    • AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo
    • Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood (2007) 110:2034-40. doi:10.1182/blood-2007-02-073700.
    • (2007) Blood , vol.110 , pp. 2034-2040
    • Yang, J.1    Ikezoe, T.2    Nishioka, C.3    Tasaka, T.4    Taniguchi, A.5    Kuwayama, Y.6
  • 73
    • 43449138516 scopus 로고    scopus 로고
    • Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts
    • Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica (2008) 93:662-9. doi:10.3324/haematol.12148.
    • (2008) Haematologica , vol.93 , pp. 662-669
    • Walsby, E.1    Walsh, V.2    Pepper, C.3    Burnett, A.4    Mills, K.5
  • 74
    • 66249093516 scopus 로고    scopus 로고
    • AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo
    • Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, et al. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo. Cancer Res (2009) 69:4150-8. doi:10.1158/0008-5472.CAN-08-3203.
    • (2009) Cancer Res , vol.69 , pp. 4150-4158
    • Oke, A.1    Pearce, D.2    Wilkinson, R.W.3    Crafter, C.4    Odedra, R.5    Cavenagh, J.6
  • 75
    • 77949693761 scopus 로고    scopus 로고
    • The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells
    • Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther (2010) 9:661-72. doi:10.1158/1535-7163.MCT-09-1144.
    • (2010) Mol Cancer Ther , vol.9 , pp. 661-672
    • Grundy, M.1    Seedhouse, C.2    Shang, S.3    Richardson, J.4    Russell, N.5    Pallis, M.6
  • 76
    • 80052713073 scopus 로고    scopus 로고
    • The clinical development of FLT3 inhibitors in acute myeloid leukemia
    • Knapper S. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opin Investig Drugs (2011) 20:1377-95. doi:10.1517/13543784.2011.611802.
    • (2011) Expert Opin Investig Drugs , vol.20 , pp. 1377-1395
    • Knapper, S.1
  • 77
    • 78649931161 scopus 로고    scopus 로고
    • Will newer tyrosine kinase inhibitors have an impact in AML?
    • Levis MJ. Will newer tyrosine kinase inhibitors have an impact in AML? Best Pract Res Clin Haematol (2010) 23:489-94. doi:10.1016/j.beha.2010.09.008.
    • (2010) Best Pract Res Clin Haematol , vol.23 , pp. 489-494
    • Levis, M.J.1
  • 78
    • 84863785488 scopus 로고    scopus 로고
    • Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
    • Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia (2012) 26:1462-70. doi:10.1038/leu.2012.52.
    • (2012) Leukemia , vol.26 , pp. 1462-1470
    • Moore, A.S.1    Faisal, A.2    Gonzalez de Castro, D.3    Bavetsias, V.4    Sun, C.5    Atrash, B.6
  • 79
    • 84867813052 scopus 로고    scopus 로고
    • Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia
    • Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, et al. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem (2012) 55:8721-34. doi:10.1021/jm300952s.
    • (2012) J Med Chem , vol.55 , pp. 8721-8734
    • Bavetsias, V.1    Crumpler, S.2    Sun, C.3    Avery, S.4    Atrash, B.5    Faisal, A.6
  • 80
    • 33750979011 scopus 로고    scopus 로고
    • Childhood tumors of the nervous system as disorders of normal development
    • Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr (2006) 18:634-8. doi:10.1097/MOP.0b013e32801080fe.
    • (2006) Curr Opin Pediatr , vol.18 , pp. 634-638
    • Grimmer, M.R.1    Weiss, W.A.2
  • 81
    • 0141617477 scopus 로고    scopus 로고
    • Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma
    • Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, et al. Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst (2003) 95:1394-403. doi:10.1093/jnci/djg045.
    • (2003) J Natl Cancer Inst , vol.95 , pp. 1394-1403
    • Burkhart, C.A.1    Cheng, A.J.2    Madafiglio, J.3    Kavallaris, M.4    Mili, M.5    Marshall, G.M.6
  • 82
    • 33748068792 scopus 로고    scopus 로고
    • Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
    • Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 66:8139-46. doi:10.1158/0008-5472.CAN-05-2769.
    • (2006) Cancer Res , vol.66 , pp. 8139-8146
    • Chesler, L.1    Schlieve, C.2    Goldenberg, D.D.3    Kenney, A.4    Kim, G.5    McMillan, A.6
  • 83
    • 81055149901 scopus 로고    scopus 로고
    • The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo
    • Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther (2011) 10:2115-23. doi:10.1158/1535-7163.MCT-11-0333.
    • (2011) Mol Cancer Ther , vol.10 , pp. 2115-2123
    • Faisal, A.1    Vaughan, L.2    Bavetsias, V.3    Sun, C.4    Atrash, B.5    Avery, S.6
  • 84
    • 34247259822 scopus 로고    scopus 로고
    • Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora A kinase
    • Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora A kinase. Proc Natl Acad Sci U S A (2007) 104:4106-11. doi:10.1073/pnas.0608798104.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 4106-4111
    • Manfredi, M.G.1    Ecsedy, J.A.2    Meetze, K.A.3    Balani, S.K.4    Burenkova, O.5    Chen, W.6
  • 85
    • 25444470823 scopus 로고    scopus 로고
    • CDC25B phosphorylation by aurora-A occurs at the G2/M transition and is inhibited by DNA damage
    • Cazales M, Schmitt E, Montembault E, Dozier C, Prigent C, Ducommun B. CDC25B phosphorylation by aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle (2005) 4:1233-8. doi:10.4161/cc.4.9.1964.
    • (2005) Cell Cycle , vol.4 , pp. 1233-1238
    • Cazales, M.1    Schmitt, E.2    Montembault, E.3    Dozier, C.4    Prigent, C.5    Ducommun, B.6
  • 87
    • 51349144633 scopus 로고    scopus 로고
    • Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
    • Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature (2008) 455:119-23. doi:10.1038/nature07185.
    • (2008) Nature , vol.455 , pp. 119-123
    • Macurek, L.1    Lindqvist, A.2    Lim, D.3    Lampson, M.A.4    Klompmaker, R.5    Freire, R.6
  • 88
    • 46249084662 scopus 로고    scopus 로고
    • Bora and the kinase aurora a cooperatively activate the kinase Plk1 and control mitotic entry
    • Seki A, Coppinger JA, Jang CY, Yates JR, Fang G. Bora and the kinase aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science (2008) 320:1655-8. doi:10.1126/science.1157425.
    • (2008) Science , vol.320 , pp. 1655-1658
    • Seki, A.1    Coppinger, J.A.2    Jang, C.Y.3    Yates, J.R.4    Fang, G.5
  • 89
    • 77953677649 scopus 로고    scopus 로고
    • The mitotic kinase aurora-A suppresses homology-directed DNA double strand-break repair
    • Sourisseau T, Maniotis M, Tang C, Lord CJ, Ashworth A, Linardopoulos S. The mitotic kinase aurora-A suppresses homology-directed DNA double strand-break repair. EMBO Mol Med (2010) 2:130-42. doi:10.1002/emmm.201000068.
    • (2010) EMBO Mol Med , vol.2 , pp. 130-142
    • Sourisseau, T.1    Maniotis, M.2    Tang, C.3    Lord, C.J.4    Ashworth, A.5    Linardopoulos, S.6
  • 90
    • 70349904767 scopus 로고    scopus 로고
    • The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe
    • Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, et al. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle (2009) 8:3172-81. doi:10.4161/cc.8.19.9729.
    • (2009) Cell Cycle , vol.8 , pp. 3172-3181
    • Tao, Y.1    Leteur, C.2    Calderaro, J.3    Girdler, F.4    Zhang, P.5    Frascogna, V.6
  • 91
    • 84900789677 scopus 로고    scopus 로고
    • The selective aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation
    • Hong X, O'Donnell JP, Salazar CR, Van Brocklyn JR, Barnett KD, Pearl DK, et al. The selective aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation. Cancer Chemother Pharmacol (2014) 73:983-90. doi:10.1007/s00280-014-2430-z.
    • (2014) Cancer Chemother Pharmacol , vol.73 , pp. 983-990
    • Hong, X.1    O'Donnell, J.P.2    Salazar, C.R.3    Van Brocklyn, J.R.4    Barnett, K.D.5    Pearl, D.K.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.